Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Virtual workshop

DH appoints new board members

Dr Catherine Bell and Dr David Heymann are to join the departmental board of the UK's Department of Health as non-executive board members

Lansley: NHS must embrace competition

UK Health Secretary, Andrew Lansley, has said the NHS needs to embrace value-based competition as part of the government’s reform plans

- PMLiVE

Dropping the ball

With the NHS 'transition' in progress, how well is industry coping with all it has to juggle?

GPs could hand flu vaccine control to DH

GPs in England could face losing responsibility for the management of flu vaccines following recent issues with supply

Health and Social Care Bill announced

The coalition government has announced the publication of the first draft for the Health and Social Care Bill 2010-11, detailing potential large-scale reforms to the NHS in England

EMIG responds on Cancer Drugs Fund

UK pharmaceutical industry group urges that new initiative must not be a forerunner to value-based pricing

ABPI urges equal access for cancer drugs

The Association of the British Pharmaceutical Industry has warned against variations in access to drugs as part of the Cancer Drugs Fund plan

UK cancer strategy launched

The Department of Health has announced the launch of a strategy to help deliver improved cancer outcomes as part of planned NHS reforms

Launch of QIPP clinical dashboard

The UK's Department of Health has announced the launch of the Urgent Care Clinical Dashboard – part of QIPP related structural changes

NICE grants final approval to Shire’s Resolor

NICE has granted approval for Resolor to be used by the NHS for treatment of certain trypes of chronic constipation

NHS mass overspend on insulin

A joint investigation from the BMJ and Channel 4 News has suggested the NHS has wasted £250m on insulin treatments over the past five years

NICE rejects Avastin for breast cancer

The National Institute for Health and Clinical Excellence has recommended against the use of Roche's Avastin for the treatment of metastatic breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links